Biotechnology

Tuesday May 31, 2022 - 10:22 am

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Major Step in Advancement of CYB003 for the Treatment of Major Depressive Disorder

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced the submission of an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”). According to the update, the IND is for Cybin’s phase 1/2a first-in-human clinical trial evaluating CYB003, a proprietary deuterated psilocybin analog, for the treatment of major depressive disorder (“MDD”). “Following the…

Friday May 27, 2022 - 2:17 pm

InvestorNewsBreaks – Why Aditxt Inc. (NASDAQ: ADTX) Is ‘One to Watch’

Aditxt (NASDAQ: ADTX) is a biotech company commercializing new innovations. The company’s first commercial product, AditxtScore(TM), is an immune mapping technology designed to provide a personalized, comprehensive profile of an individual’s immune system. “The company’s first commercial application of the platform, AditxtScore(TM) for COVID-19, delivers timely reports on vulnerability and immune status relating to SARS-CoV-2 and its known variants, giving consumers and physicians the data…

Tuesday May 24, 2022 - 12:31 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Announces Issuance of Circular, Incentive Plan and Granting of PSUs

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced that it has issued a management information circular in respect of the annual general meeting of shareholders to be held on June 23, 2022. The circular is available on the company’s profile on SEDAR at www.SEDAR.com. In addition, to provide…

Tuesday May 24, 2022 - 10:05 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at H.C. Wainwright Global Investment Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its CEO John Climaco will be participating at the H.C. Wainwright Global Investment Conference. The event is slated to take place May 23-26, 2022, virtually and in-person in Miami, Florida. A video webcast of Climaco’s presentation…

Monday May 23, 2022 - 1:49 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Among Most Powerful of Chemotherapy Drugs

CNS Pharmaceuticals’ (NASDAQ: CNSP) novel anthracycline Berubicin, which has been developed to treat diseases with unmet need such as the deadly glioblastoma (“GBM”), appears to be the first anthracycline chemotherapy agent to successfully cross the blood-brain barrier in targeting tumors of the central nervous system. “Berubicin was the drug candidate subject of a small-scale phase 1 clinical trial in 2006 that evaluated its safety, which…

Monday May 23, 2022 - 1:39 pm

InvestorNewsBreaks – Silo Pharma Inc. (SILO) Bringing Hope to Patients Suffering from Alzheimer’s and Potentially Other Ailments

Silo Pharma (OTCQB: SILO) is exploring the efficacy of ketamine in treating patients suffering from both Alzheimer’s and Parkinson’s disease. With more than 80% of Parkinson’s patients and 75% of Alzheimer’s patients experiencing dysphagia, difficulty or complete inability to swallow, last year, SILO entered into a joint venture with Zylö Therapeutics. Under the collaboration, the companies will explore an innovative technology – ZTI’s Z-pod transdermal…

Monday May 23, 2022 - 1:11 pm

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Partners to Help Accelerate Regulatory Pathway of CYB003

Cybin (NYSE American: CYBN) (NEO: CYBN) is moving forward with its phase 1/2a clinical trial of its proprietary deuterated psilocybin, CYB003, which, previous research shows, has the potential to effectively treat major depressive disorder (“MDD”) with significant advantages over classic psilocybin. MDD impacts over 264 million people worldwide, 1/3 to 1/2 of whom demonstrate an inadequate response to antidepressant drug treatment. Against this backdrop, Cybin…

Thursday May 19, 2022 - 11:21 am

InvestorNewsBreaks – Silo Pharma Inc. (SILO) Announces Milestone in Psilocybin Study on Parkinson’s Patients

Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that, in conjunction with the University of California San Francisco (“UCSF”), researchers have successfully dosed patients suffering from Parkinson’s disease. As part of the study, researchers are collecting blood samples to determine the effects of psilocybin on inflammatory markers of patients who have exhibited signs of…

Thursday May 19, 2022 - 10:50 am

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) to Participate in H.C. Wainwright Global Hybrid Investment Conference

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs, and its CEO Dr. Faz Chowdhury will be attending the upcoming H.C. Wainwright Global Hybrid Investment Conference. The conference is slated for May 23–26, 2022, in Miami Beach, Florida. Chowdhury has been invited to present during the event; his virtual presentation is slated…

Wednesday May 18, 2022 - 11:08 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Abstract to be Presented at American Society of Clinical Oncology 2022 Annual Meeting

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced acceptance of its abstract for poster presentation at the American Society of Clinical Oncology (“ASCO”) 2022 Annual Meeting. Being held virtually and in Chicago, Illinois, the event is slated to take place from June 3-7, 2022. The…

Wednesday May 18, 2022 - 11:01 am

InvestorNewsBreaks – Silo Pharma Inc. (SILO) CEO Featured in Bell2Bell Podcast Episode

Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, and its founder and CEO Eric Weisblum are the center of attention in the most recent episode of the Bell2Bell Podcast. The Bell2Bell Podcast is designed to provide informative updates and exclusive interviews with executives operating in fast-moving industries. During the interview, hosted by Stuart Smith, Weisblum talks…

Monday May 16, 2022 - 2:45 pm

InvestorNewsBreaks – Creative Medical Technology (NASDAQ: CELZ) Expects $17 Million Gross Proceeds from Private Placement

Creative Medical Technology Holdings (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, has entered into a securities purchase agreement. The agreement with several institutional investors to purchase more than 7.5 million shares of common stock or common stock equivalents in a private placement. The shares will be priced at market value. In addition, Creative…

Monday May 16, 2022 - 12:09 pm

InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Issues Update on Default Status

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, announced that it is providing a default status report; the report is being released in accordance with the alternative information guidelines set out in National Policy 12-203 — Management Cease Trade Orders (“NP 12-203”). According to the announcement, Delic is experiencing delays to its audit, which means…

Monday May 16, 2022 - 11:58 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q1 2022 Financial, Corporate Update

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has released its first quarter 2022 financial report along with key updates on company strategies. The report pointed to recent approvals of a potentially pivotal Berubicin study in Europe that is expected to significantly drive patient enrollment and opportunities…

Friday May 13, 2022 - 10:53 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Q3 Fiscal 2022 Financial Results, Provides Business Update

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the research, development, manufacturing and commercialization of rare cannabinoids. The company today announced financial results for the third quarter ended March 31, 2022. “The third quarter of fiscal 2022 saw noticeable advancements across all of our programs, including commencing sales of the rare cannabinoids CBDV and CBT as raw ingredients for the health and wellness industry,” said…

Wednesday May 11, 2022 - 10:17 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) Featured in InvestmentPitch Media Video

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, has closed the sale of non-core assets for $16.4 million. This news and additional information about the company was featured in an InvestmentPitch Media video, available for viewing on InvestmentPitch and YouTube or by visiting www.InvestmentPitch.com and entering “FSD Pharma” in the…

Tuesday May 10, 2022 - 11:20 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Kernel Share Preliminary Results from Flow Feasibility Study

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its partner Kernel, are reporting preliminary data that confirm the ability of Kernel’s quantitative neuroimaging technology, Flow, to successfully measure neuro-effect of ketamine. Kernel is a leader in noninvasive neuroimaging. According to the announcement, results of a Cybin-sponsored feasibility study indicate that ketamine-induced changes in functional connectivity continued for several…

Tuesday May 10, 2022 - 10:32 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Closes CAD$16.4M Sale of Non-Core Assets

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced the closing of the sale of the company’s former cannabis processing facility located in Cobourg, Ontario, Canada, for gross proceeds of CAD$16,400,000 in cash. “This is a major accomplishment and puts us in a good position going forward especially considering…

Monday May 09, 2022 - 2:14 pm

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Leveraging Advantage in Rare Cannabinoid Biosynthesis Space

InMed Pharmaceuticals (NASDAQ: INM) is a clinical-stage company currently developing a pipeline of cannabinoid-based pharmaceutical drug candidates to treat several diseases with high, unmet medical needs. The company’s focus is on rare cannabinoids, many of which are not yet available in commercial-size quantities, such as cannabidivarin – (“CBDV”) and tetrahydrocannabivarin – (“THCV”). “The acquisition of BayMedica in October 2021 has provided an advantage for InMed…

Monday May 09, 2022 - 12:56 pm

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Announces Positive Results from Phase I Clinical Trial for Novel Drug to Treat Concussion

Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., a company focused on developing unique, life-saving medical products, has announced positive results from the first group of patients dosed with PRV-002 in its phase I clinical trial. According to the update, Odyssey’s trial is administering PRV-002, its novel drug to treat concussion, to healthy human subjects. Thus far, the drug has shown to be safe…

Friday May 06, 2022 - 2:16 pm

InvestorNewsBreaks – Silo Pharma Inc. (SILO), Frontage Laboratories to Collaborate in Pharmacokinetic Study

Silo Pharma (OTCQB: SILO) recently announced an agreement with Frontage Laboratories, a contract research organization, for an Investigational New Drug (“IND”)-enabling pharmacokinetic study. “Silo merges traditional therapeutics with psychedelic research to relieve patients suffering from PTSD, Alzheimer’s, Parkinson’s, and other rare neurological disorders,” a recent article reads. “Frontage will study Silo’s central nervous system peptide, SPU-16, ’a potential new treatment for multiple sclerosis and other…

Thursday May 05, 2022 - 3:01 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Demonstrating ‘Encouraging Promise in Treatment of GBM’

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical cancer drug developer, recently reported new advances in its rollout of a global clinical trial described as “potentially pivotal” in producing a treatment for an aggressive brain cancer, glioblastoma multiforme (“GBM”). On average, GBM is nearly 100% fatal just over a year into diagnosis. “CNS announced that France’s regulatory agencies have granted the company authority to pursue patient recruitment…

Wednesday May 04, 2022 - 1:15 pm

InvestorNewsBreaks – IBN’s BioMedWire to Raise Visibility of 2nd Annual Gene Therapy Patient Engagement Summit

IBN (“InvestorBrandNetwork”), an innovative content distributor and multifaceted communications organization with 50+ brands including BioMedWire (“BMW”), today announced that it will be collaborating with Hanson Wade as an official media sponsor for the upcoming 2nd Annual Gene Therapy Patient Engagement Summit. The event is slated to take place from June 7-9, 2022, in Boston, Massachusetts, and unite patient advocacy groups, engagement leaders and the patients…

Wednesday May 04, 2022 - 10:14 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Transition from Pure-Play Pharma R&D Firm Featured in Research Report

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, was featured in a report published by Edison Group, a leading research and investor relations consultancy. The piece details InMed Pharmaceuticals and its continued “transition from a pure-play pharma R&D firm to one also benefiting from commercial sales into the health and wellness market. Product launches of high-value, rare…

Tuesday May 03, 2022 - 10:12 am

InvestorNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Announces Launch of Physician-Focused Ads as Part of Large-Scale Campaign Around sugarBEAT(R)

Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing wearable diagnostic devices and supporting personalized lifestyle coaching programs. The company today announced that its U.K. licensee, MySugarWatch, as part of a large scale awareness campaign for the company’s sugarBEAT non-invasive continuous glucose monitor, has launched a series of ads in one the U.K.’s preeminent physician and pharmacist education resources, MIMS.…

Thursday Apr 28, 2022 - 2:41 pm

InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Advancing Pipeline in Commitment to Transform Mental Health Treatment Landscape

Cybin (NYSE American: CYBN) (NEO: CYBN) is a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions in a commitment to transform the mental health treatment landscape. Through its proprietary deuterated process, Cybin is combining controllable drug-delivery systems with novel psychedelic molecules, thus creating patent-protected, commercially scalable drug candidates. “The company currently is moving three of these drug candidates…

Thursday Apr 28, 2022 - 12:59 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”). The company today announced its receipt of approval from the Spanish Agency for Medicines and Health Products (“AEMPS”) Competent Authority and from the CElm Provincial de Sevilla Ethics Committee in Spain for CNSP’s potentially pivotal study of…

Thursday Apr 28, 2022 - 11:20 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expands Patent Portfolio with Novel Cannabinoid Analogs, Initiates Strategic Research Collaboration Agreement

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced the publication of a patent application in North America. The application has broad claims directed to the molecular structure, uses and methods of manufacturing of several cannabinoid analogs. Describing several new cannabinoid-related chemical compounds, the broad patent application, if granted, allows for the creation of several variations…

Friday Apr 22, 2022 - 1:28 pm

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Focused on Advancing Research on Treatments for GBM, Other Cancers

CNS Pharmaceuticals (NASDAQ: CNSP) is leading the charge toward advancing research on the treatment for glioblastoma multiforme (“GBM”) as well as other primary and metastatic brain and CNS cancers. Last year, the company commenced a potentially pivotal clinical trial of its lead product candidate, Berubicin, for the treatment of GBM, dosing its first patients in September. A recent article discussing this reads, “CNS Pharmaceuticals expects…

Friday Apr 22, 2022 - 9:39 am

InvestorNewsBreaks — AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) to Conduct Key Research with TransBIOTech, Names New COO

AREV Life Sciences Global (CSE: AREV) (OTC: AREVF) has partnered with TransBIOTech, a publicly supported preclinical research organization, in a project to research cannabinoids and other early-stage commercial programs. TransBIOTech works with and is supported by the Canadian government through the Natural Sciences and Engineering Research Council (“NSERC”) in collaboration with the Canadian Institutes of Health Research (“CIHR”). AREV and TransBIOTech will work together to…

Thursday Apr 21, 2022 - 12:39 pm

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Strategic Advisory Board Appointments

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A),a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today announced the appointment of David Allan and John McGraw, PhD, MSc, to the company’s advisory board. Allan is the 2017 recipient of the prestigious Julia Levy Award and will collaborate with 2021 Julia Levy Award winner Dr. Lakshmi P. Kotra, CEO of…

Thursday Apr 21, 2022 - 10:50 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Expansion of Rare Cannabinoid Portfolio

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, is launching business-to-business sales of its rare cannabinoid cannabidivarin (“CBDV”). Through subsidiary BayMedica LLC, InMed will offer its product to wholesalers, suppliers and end-product manufacturers in the health and wellness sector. In addition, the company released a white paper focused on research into the therapeutic potential of CBDV. According…

Wednesday Apr 20, 2022 - 11:02 am

InvestorNewsBreaks – Silo Pharma Inc. (SILO) Produces First Batch of SPU-21 Liposomes for RA Study

Silo Pharma (OTCQB: SILO) is a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic. The company today announced that it has produced its first batch of liposomes for use in a preclinical study that will be conducted by Frontage Laboratories, a CRO (contract research organization). According to the update, the ability of the SPU-21 to target inflamed epithelium suggest their potential…

Tuesday Apr 19, 2022 - 9:57 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Participation in Upcoming Conferences

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, will be involved in several conferences in April and May. Company management will be participating at the Benzinga Spring Cannabis Capital Conference, scheduled for April 20–21, 2022, in Miami Beach, Florida. InMed executives will be meeting virtually with institutions and industry representatives. Company executives will also be at Canaccord…

Monday Apr 18, 2022 - 2:36 pm

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expanding Rare Cannabinoid Manufacturing Scale

InMed Pharmaceuticals (NASDAQ: INM), a rare cannabinoid drug developer, is expanding its product manufacturing scale, thanks largely to the acquisition of consumer-focused rare cannabinoids manufacturer BayMedica last year. “InMed’s most-recent Q2 financial statement reported revenues of $0.3 million from commercial sales of cannabichromene (‘CBC’) to the health and wellness market following the BayMedica acquisition. Since January, the company has also been selling cannabicitran (‘CBT’) to…

Tuesday Apr 12, 2022 - 11:00 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate in Upcoming Virtual Investor Event

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be part of a moderated fireside chat during the Virtual Investor Glioblastoma Multiforme (“GBM”) Spotlight event on April 14, 2022. The chat is scheduled for 11:30 a.m. ET and will include CNS Pharmaceuticals management team members, including CEO John…

Friday Apr 08, 2022 - 1:31 pm

InvestorNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Working to Capitalize on Psychedelics Therapeutics Market’s Growth

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) is a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders. A recent article discusses the company’s efforts to lead the charge toward developing novel psychedelic and non-psychedelic molecules for medical use. “Its research and development efforts have focused on compounds that can enable safer and more effective treatments for patients dealing with…

Thursday Apr 07, 2022 - 2:22 pm

InvestorNewsBreaks – Why Silo Pharma Inc. (SILO) Is ‘One to Watch’

Silo Pharma (OTCQB: SILO) is committed to developing innovative solutions to address various underserved conditions such as post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s, Parkinson’s, and other rare neurological disorders as part of its focus on merging traditional therapeutics with psychedelic research. “Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research…

Wednesday Apr 06, 2022 - 11:37 am

InvestorNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Approval from France EC and ANSM Competent Authority for Potentially Pivotal Study of Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system (“CNS”), today announced its receipt of approval from the National Agency for the Safety of Medicine and Health Products (“ANSM”) Competent Authority and from the People Protection Ethics Committee (“EC”) SUD-EST III (“CPP Sud-Est III”) in France for the…

Wednesday Apr 06, 2022 - 11:17 am

InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) to Participate in Upcoming Benzinga Psychedelics Capital Conference

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be represented at the Benzinga Psychedelics Capital Conference. The premier event is scheduled for April 19, 2022, and will be held in Miami Beach, Florida. Cybin CEO Doug Drysdale will present a fireside chat and will also be a member of a panel discussion. Drysdale’s chat is slated to start…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions